ArticleFrontiers in pharmacology2026
GLP-1 agonist liraglutide decreases operant methamphetamine intake in rats under conditions of short- but not extended-access to the drug.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a therapeutic strategy for reducing drug craving and intake. However, their efficacy in methamphetamine use disorder remains unexplored. This study assessed the effects of repeated liraglutide treatment on methamphetamine intravenous self-administration in rats. Methods: Male Wistar rats were trained to self-administer methamphetamine in either short- (1.5-h) or extended- (6-h) access sessions. Once a stable level of drug intake was achieved, the animals received daily subcutaneous injections of liraglutide (0.1 mg/kg) or saline for 7 days, administered 1 hour before the session. Results: Operant responding and methamphetamine intake were significantly higher in the extended-access protocol, and the drug intake showed an escalation in time. A single administration of liraglutide did not affect methamphetamine intake in either the short- or extended-access paradigms. Following repeated administration, liraglutide significantly decreased methamphetamine intake in the short-but not in the extended-access study. Conclusion: The findings suggest that the GLP-1 receptor agonist liraglutide can reduce methamphetamine-taking behavior under conditions of low intake, whereas in the extended-access protocol, where drug intake escalates, the treatment shows no effect. Further research should better characterize its optimal dosing, duration of action, and brain penetration in rats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.